A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy

Journal of Clinical Investigation

Volumn 118, Issue 5, 2008, Pages 1669-1679

  Fritsch, Anja ^a   Loeckermann, Stefan ^a   Kern, Johannes S ^a,b   Braun, Attila ^c   Bösl, Michael R ^c   Bley, Thorsten A ^a   Schumann, Hauke ^a   Von Elverfeldt, Dominik ^a   Paul, Dominik ^a   Erlacher, Miriam ^a   Von Rautenfeld, Dirk Berens ^d   Hausser, Ingrid ^e   Fässler, Reinhard ^c   Bruckner Tuderman, Leena ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 7; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; CELL THERAPY; CONTROLLED STUDY; DEFORMITY; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; FIBROBLAST; GROWTH RETARDATION; HISTOPATHOLOGY; HOMOZYGOSITY; LIFE EXPECTANCY; MALE; MALNUTRITION; MOUSE; MYOFIBROBLAST; NAIL DYSTROPHY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL BLISTER; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; TISSUE REPAIR; TREATMENT RESPONSE;

ANIMALS; CELLS, CULTURED; COLLAGEN TYPE VII; DISEASE MODELS, ANIMAL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; FIBROBLASTS; FOOT DEFORMITIES, CONGENITAL; FORELIMB; HAND DEFORMITIES, CONGENITAL; HUMANS; MALE; MALNUTRITION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; RNA SPLICING; SKIN;

EID: 43049093343     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34292     Document Type: Article

References (44)

1. Has, C., and Bruckner-Tuderman, L. 2006. Molecular and diagnostic aspects of genetic skin fragility. J. Dermatol. Sci. 44:129-144.
2. Ryynanen, J., et al. 1992. Type VII collagen gene expression by cultured human cells and in fetal skin. Abundant mRNA and protein levels in epidermal keratinocytes. J. Clin. Invest. 89:163-168.
3. Rattenholl, A., et al. 2002. Proteinases of the bone morphogenetic protein-1 family convert procollagen VII to mature anchoring fibril collagen. J. Biol. Chem. 277:26372-26378.
4. Aumailley, M., Has, C., Tunggal, L., and Bruckner-Tuderman, L. 2006. Molecular basis of inherited skin-blistering disorders, and therapeutic implications. Expert Rev. Mol. Med. 8:1-21.
5. Fine, J.D., McGrath, J., and Eady, R.A. 2000. Inherited epidermolysis bullosa comes into the new millenium: a revised classification system based on current knowledge of pathogenetic mechanisms and the clinical, laboratory, and epidemiologic findings of large, well-defined patient cohorts. J. Am. Acad. Dermatol. 43:135-137.
6. Kern, J.S., Kohlhase, J., Bruckner-Tuderman, L., and Has, C. 2006. Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa. J. Invest. Dermatol. 126:1006-1012.
7. Varki, R., Sadowski, S., Uitto, J., and Pfendner, E. 2007. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J. Med. Genet. 44:181-192.
8. Bhowmick, N.A., et al. 2004. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 303:848-851.
9. Heinonen, S., et al. 1999. Targeted inactivation of the type VII collagen gene (Col7a1) in mice results in severe blistering phenotype: a model for recessive dystrophic epidermolysis bullosa. J. Cell Sci. 112:3641-3648.
10. Cao, T., Longley, M.A., Wang, X.J., and Roop, D.R. 2001. An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy. J. Cell Biol. 152:651-656.
11. Rodgers, K.D., Sasaki, T., Aszodi, A., and Jacenko, O. 2007. Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome. Hum. Mol. Genet. 16:515-528.
12. Vermot, J., Niederreither, K., Garnier, J.M., Chambon, P., and Dolle, P. 2003. Decreased embryonic retinoic acid synthesis results in a DiGeorge syndrome phenotype in newborn mice. Proc. Natl. Acad. Sci. U. S. A. 100:1763-1768.
13. Lupher, M.L., Jr., and Gallatin, W.M. 2006. Regulation of fibrosis by the immune system. Adv. Immunol. 89:245-288.
14. Hinz, B. 2007. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127:526-537.
15. Chiquet-Ehrismann, R., and Chiquet, M. 2003. Tenascins: regulation and putative functions during pathological stress. J. Pathol. 200:488-499.
16. Martin, P., and Leibovich, S.J. 2005. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 15:599-607.
17. Werner, S., Krieg, T., and Smola, H. 2007. Keratinocyte-fibroblast interactions in wound healing. J. Invest. Dermatol. 127:998-1008.
18. Hinz, B., et al. 2007. The myofibroblast. One function, multiple origins. Am. J. Pathol. 170:1807-1816.
19. Gabbiani, G. 2003. The myofibroblast in wound healing and fibrocontractive diseases. J. Pathol. 200:500-503.
20. Ingber, D.E. 2002. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation. 70:547-560.
21. Coussens, L.M., and Werb, Z. 2002. Inflammation and cancer. Nature. 420:860-867.
22. Maeda, H., and Akaike, T. 1998. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry Mosc. 63:854-865.
23. Yamanishi, Y., et al. 2002. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. U. S. A. 99:10025-10030.
24. Hayashi, N., and Cunha, G.R. 1991. Mesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinoma. Cancer Res. 51:4924-4930.
25. Cooper, M., and Pinkus, H. 1977. Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. 37:2544-2552.
26. Gache, Y., et al. 2004. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum. Gene Ther. 15:921-933.
27. Ortiz-Urda, S., et al. 2002. Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 8:1166-1170.
28. Woodley, D.T., et al. 2004. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol. Ther. 10:318-326.
29. Woodley, D.T., et al. 2003. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J. Invest. Dermatol. 121:1021-1028.
30. Ortiz-Urda, S., et al. 2003. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J. Clin. Invest. 111:251-255.
31. Woodley, D.T., et al. 2004. Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa. Nat. Med. 10:693-695.
32. Sitaru, C., et al. 2005. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J. Clin. Invest. 115:870-878.
33. Woodley, D.T., et al. 2005. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J. Invest. Dermatol. 124:958-964.
34. Bruckner-Tuderman, L., Guscetti, F., and Ehrensperger, F. 1991. Animal model for dermolytic mechanobullous disease: sheep with recessive dystrophic epidermolysis bullosa lack collagen VII. J. Invest. Dermatol. 96:452-458.
35. Baldeschi, C., et al. 2003. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum. Mol. Genet. 12:1897-1905.
36. Wong, T., et al. 2007. A single intradermal injection of allogeneic fibroblasts can increase type VII collagen expression in recessive dystrophic epidermolysis bullosa for at least 3 months [supplement]. J. Invest. Dermatol. 127:S91.
37. Hilal, L., et al. 1993. A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa. Nat. Genet. 5:287-293.
38. Krueger, G.G., Morgan, J.R., and Petersen, M.J. 1999. Biologic aspects of expression of stably integrated transgenes in cells of the skin in vitro and in vivo. Proc. Assoc. Am. Physicians. 111:198-205.
39. Talts, J.F., Brakebusch, C., and Fassler, R. 1999. Integrin gene targeting. Methods Mol. Biol. 129:153-187.
40. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., and Roder, J.C. 1993. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 90:8424-8428.
41. Zaha, V., et al. 2005. Discrepancy between GLUT4 translocation and glucose uptake after ischemia. Mol. Cell. Biochem. 278:129-137.
42. Caldelari, R., Suter, M.M., Baumann, D., De Bruin, A., and Muller, E. 2000. Long-term culture of murine epidermal keratinocytes. J. Invest. Dermatol. 114:1064-1065.
43. Echtermeyer, F., et al. 2001. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J. Clin. Invest. 107:R9-R14.
44. Bruckner-Tuderman, L., et al. 1995. Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain. J. Cell Biol. 131:551-559.